Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Vitamin D in the aetiology and management of polycystic ovary syndrome.

Thomson RL, Spedding S, Buckley JD.

Clin Endocrinol (Oxf). 2012 Sep;77(3):343-50. doi: 10.1111/j.1365-2265.2012.04434.x. Review.

PMID:
22574874
2.

[The role of vitamin D deficiency in the etiology of polycystic ovary syndrome disorders].

Brzozowska M, Karowicz-Bilińska A.

Ginekol Pol. 2013 Jun;84(6):456-60. Review. Polish.

PMID:
24032264
3.

Vitamin D supplementation has no effect on insulin resistance assessment in women with polycystic ovary syndrome and vitamin D deficiency.

Ardabili HR, Gargari BP, Farzadi L.

Nutr Res. 2012 Mar;32(3):195-201. doi: 10.1016/j.nutres.2012.02.001.

PMID:
22464806
4.

Therapeutic effects of calcium & vitamin D supplementation in women with PCOS.

Firouzabadi Rd, Aflatoonian A, Modarresi S, Sekhavat L, MohammadTaheri S.

Complement Ther Clin Pract. 2012 May;18(2):85-8. doi: 10.1016/j.ctcp.2012.01.005. Epub 2012 Feb 20.

PMID:
22500844
5.

Effects of vitamin D on cardiovascular disease risk factors in polycystic ovary syndrome women with vitamin D deficiency.

Rahimi-Ardabili H, Pourghassem Gargari B, Farzadi L.

J Endocrinol Invest. 2013 Jan;36(1):28-32. doi: 10.3275/8303. Epub 2012 Mar 22.

PMID:
22453059
6.

Vitamin D as a predictor of insulin resistance in polycystic ovarian syndrome.

Patra SK, Nasrat H, Goswami B, Jain A.

Diabetes Metab Syndr. 2012 Jul-Sep;6(3):146-9. doi: 10.1016/j.dsx.2012.09.006. Epub 2012 Oct 23.

PMID:
23158978
7.

Role of vitamin D in ovarian physiology and its implication in reproduction: a systematic review.

Irani M, Merhi Z.

Fertil Steril. 2014 Aug;102(2):460-468.e3. doi: 10.1016/j.fertnstert.2014.04.046. Epub 2014 Jun 3. Review.

PMID:
24933120
8.

Use of insulin sensitizers in polycystic ovarian syndrome.

Baillargeon JP.

Curr Opin Investig Drugs. 2005 Oct;6(10):1012-22. Review.

PMID:
16259222
9.

Vitamin D Supplementation Decreases TGF-β1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial.

Irani M, Seifer DB, Grazi RV, Julka N, Bhatt D, Kalgi B, Irani S, Tal O, Lambert-Messerlian G, Tal R.

J Clin Endocrinol Metab. 2015 Nov;100(11):4307-14. doi: 10.1210/jc.2015-2580. Epub 2015 Oct 20.

PMID:
26485217
10.

Vitamin D and cardiometabolic risk factors and diseases.

Mousa A, Naderpoor N, Teede HJ, De Courten MP, Scragg R, De Courten B.

Minerva Endocrinol. 2015 Sep;40(3):213-30. Epub 2015 Feb 25. Review.

PMID:
25714787
11.

The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review.

Krul-Poel YH, Snackey C, Louwers Y, Lips P, Lambalk CB, Laven JS, Simsek S.

Eur J Endocrinol. 2013 Oct 23;169(6):853-65. doi: 10.1530/EJE-13-0617. Print 2013 Dec. Review.

12.

Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome.

Hahn S, Haselhorst U, Tan S, Quadbeck B, Schmidt M, Roesler S, Kimmig R, Mann K, Janssen OE.

Exp Clin Endocrinol Diabetes. 2006 Nov;114(10):577-83.

PMID:
17177140
13.

Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome.

Li HW, Brereton RE, Anderson RA, Wallace AM, Ho CK.

Metabolism. 2011 Oct;60(10):1475-81. doi: 10.1016/j.metabol.2011.03.002. Epub 2011 May 6.

PMID:
21550088
14.

Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome.

Sathyapalan T, Shepherd J, Arnett C, Coady AM, Kilpatrick ES, Atkin SL.

Clin Chem. 2010 Nov;56(11):1696-700. doi: 10.1373/clinchem.2010.144014. Epub 2010 Sep 3.

15.

Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome.

Panidis D, Balaris C, Farmakiotis D, Rousso D, Kourtis A, Balaris V, Katsikis I, Zournatzi V, Diamanti-Kandarakis E.

Clin Chem. 2005 Sep;51(9):1691-7. Epub 2005 Jul 21.

16.

Polycystic ovary (Stein-Leventhal) syndrome: etiology, complications, and treatment.

Hoyt KL, Schmidt MC.

Clin Lab Sci. 2004 Summer;17(3):155-63. Review.

PMID:
15314890
17.

The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome.

Diamanti-Kandarakis E, Kandaraki E, Christakou C, Panidis D.

Obes Rev. 2009 Jul;10(4):431-41. doi: 10.1111/j.1467-789X.2009.00588.x. Epub 2009 Apr 21. Review.

PMID:
19413702
18.

A pilot study: effects of decreasing serum insulin with diazoxide on vitamin D levels in obese women with polycystic ovary syndrome.

Nestler JE, Reilly ER, Cheang KI, Bachmann LM, Downs RW Jr.

Trans Am Clin Climatol Assoc. 2012;123:209-19; discussion 219-20.

19.

Metformin in polycystic ovary syndrome.

Diamanti-Kandarakis E, Economou F, Palimeri S, Christakou C.

Ann N Y Acad Sci. 2010 Sep;1205:192-8. doi: 10.1111/j.1749-6632.2010.05679.x. Review.

PMID:
20840272
20.

Effect of vitamin D3 treatment on glucose metabolism and menstrual frequency in polycystic ovary syndrome women: a pilot study.

Wehr E, Pieber TR, Obermayer-Pietsch B.

J Endocrinol Invest. 2011 Nov;34(10):757-63. doi: 10.3275/7748. Epub 2011 May 24.

PMID:
21613813

Supplemental Content

Support Center